Published in Gene Therapy Weekly, July 12th, 1999
The use of gene therapy to treat human disease currently is restricted by the relatively low efficiency and potential hazards of methods of oligonucleotide or gene delivery. While antisense or transcription factor decoy oligonucleotides have altered gene expression in cell culture experiments, their in vivo application is limited by the efficiency of cellular delivery, the intracellular stability of the compounds, and their duration of activity, noted Michael J. Mann, Harvard Medical School, Boston, Massachusetts, and colleagues.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.